



Adolescent Vaccination Best Practices in Meningococcal B Disease Prevention

Thursday, December 7, 2017 | 12 - 1 PM Central Time

Click to register now at: goo.gl/ST7dj8

Description

Meningococcal disease, specifically serotype B (MenB), is an ongoing problem in this country, particularly in light of recent university outbreaks. The disease can develop from initial symptoms to death within 24 hours, and as many as 20% of survivors have permanent sequelae. Notably, incidence rates are often a misconception due to underdetection and under-reporting. Given how disabling diseases can be that could have been prevented with vaccination, it is essential that healthcare workers delivering vaccinations enhance their standards of care in practice in order to deliver the highest rates of preventative care. The goal of the activity is to improve comprehension and initiate practice changes so as to improve immunization rates for all patients who are currently scheduled for the MenB vaccination.

Learning Objectives

At the conclusion of this activity, participants will be able to (or better able to):

- Discuss the current epidemiology of MenB in the United States and the profiles of patients at greatest risk for this vaccine-preventable disease.
- Describe recent MenB immunization recommendations made by the Advisory Committee on Immunization Practices (ACIP) and the rationale behind a category B classification.
- Examine the mechanism of action, contraindications, and adverse effect profiles of current MenB vaccines.
- Given a patient case, recognize best practices in counseling patients and their parents/caregivers on the importance of administering the MenB vaccine.
- Discuss practice considerations for administering the MenB vaccine such as documentation, billing, and screening for additional immunizations.

Target Audience

The target audience includes pediatricians and other clinicians who specialize in adolescent health, college health and immunization who care for patients who are scheduled to receive the Meningococcal B vaccine.

Speakers

Gary Marshall, MD

Professor of Pediatrics, Chief, Division of Pediatric Infectious Diseases University of Louisville School of Medicine, Louisville, KY

Hank Bernstein, DO - Course Co-Director

Professor of Pediatrics Chief of Division of Pediatrics North Shore University Hospital Professor, Hofstra Northwell School of Medicine, New York, NY

Planning:

Stephen I. Pelton, MD - Course Director

Professor of Pediatrics - Boston University School of Medicine Professor of Epidemiology Boston University School of Public Health Director, Section of Pediatric Infectious Diseases

Boston Medical Center

Carole Moloney, RN, MSN, CPNP

Clinical Instructor of Pediatrics Boston University School of Medicine Pediatric Infectious Diseases - Boston Medical Center

Accreditation

Boston University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Boston University School of Medicine designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAP Accreditation

This continuing medical education activity has been reviewed by the American Academy of Pediatrics and is acceptable for a maximum of 1.00 AAP credits. These credits can be applied toward the AAP CME/CPD Award available to Fellows and Candidate Members of the American Academy of Pediatrics

Commercial Support

This educational activity is supported by an educational grant from Pfizer.



